Other Events ·
Radiopharm Theranostics announced positive Phase 1 imaging trial data for RAD301 in patients with Pancreatic Ductal…
RADXRadiopharm Theranostics Ltd
Radiopharm Theranostics announced positive Phase 1 imaging trial data for RAD301 in patients with Pancreatic Ductal Adenocarcinoma (PDAC). The peptide-based molecule, bound to Gallium-68 and targeting αvβ6-integrin, demonstrated a favorable safety profile, significant tumor uptake in metastases, and low background uptake in the liver, lung, and bowel. These findings support the compound's potential for disease detection and patient selection, prompting plans to advance RAD301 into Phase 2 development. Radiopharm Theranostics is a clinical-stage biopharmaceutical company developing innovative oncology radiopharmaceuticals for diagnostic and therapeutic applications.